Phagelux Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 5

Phagelux General Information

Description

Developer of bacteriophages designed to provide alternatives to antibiotics for multiple fields. The company offers anti-bacterial products across multiple fields utilizing various phage and phage-based technologies, enabling medical users to solve the bacterial problem and provide treatments to various diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Corporate Office
  • Room 309, No. 88, Meiliang Road, Mashan Street
  • Binhu District
  • Wuxi, Jiangsu 214026
  • China
+86 151 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Phagelux Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 14-Nov-2022 0000 Completed Generating Revenue
4. Later Stage VC (Series B) 10-Feb-2022 0000 Completed Generating Revenue
3. Later Stage VC 06-Aug-2021 0000 Completed Generating Revenue
2. Early Stage VC (Series A) 09-Jun-2015 $10M $10M Completed Generating Revenue
1. Early Stage VC 06-Mar-2014 Completed Generating Revenue
To view Phagelux’s complete valuation and funding history, request access »

Phagelux Patents

Phagelux Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3299459-B1 Staphylococcus lyase and use thereof Active 18-May-2015 0000000000
EP-3299459-A1 Staphylococcus lyase and use thereof Active 18-May-2015 0000000000
EP-3299459-A4 Staphylococcus lyase and use thereof Active 18-May-2015 0000000000 0
EP-3312275-A1 Broad spectrum of streptococcus lyase and use thereof Active 13-Apr-2015 000000000
EP-3312275-B1 Antibiotic chimeric lyase from streptococcus and uses thereof Active 13-Apr-2015 C12N9/88
To view Phagelux’s complete patent history, request access »

Phagelux Executive Team (5)

Name Title Board Seat Contact Info
Mark Engel Founder, Chairman & Chief Executive Officer
Matthew Tebeau Chief Operating Officer
You’re viewing 2 of 5 executive team members. Get the full list »

Phagelux Board Members (1)

Name Representing Role Since
Mark Engel Phagelux Founder, Chairman & Chief Executive Officer 000 0000
To view Phagelux’s complete board members history, request access »

Phagelux Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Moom Capital Venture Capital Minority 000 0000 000000 0
Wuxi Capital Government Minority 000 0000 000000 0
BioTrack Capital Venture Capital Minority 000 0000 000000 0
Fosun Pharma Corporation Minority 000 0000 000000 0
WuXi Healthcare Investment Consulting Corporate Venture Capital Minority 000 0000 000000 0
To view Phagelux’s complete investors history, request access »

Phagelux Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nexabiome 15-Mar-2021 00000 0000 00.000 Biotechnology
Scithera Microbial Technologies 14-Oct-2015 0000000000 Biotechnology 0000000 0
OmniLytics (Multi-line Chemicals) 20-Jul-2015 0000000000 Multi-line Chemicals 0000 0000
Iveria Technologies (Novel Delivery Systems) 23-Dec-2014 Merger/Acquisition Drug Delivery
To view Phagelux’s complete investments and acquisitions history, request access »

Phagelux Subsidiaries (1)

Company Name Industry Location Founded
OmniLytics (Multi-line Chemicals) Multi-line Chemicals Sandy, UT 0000
To view Phagelux’s complete subsidiaries history, request access »

Phagelux FAQs

  • When was Phagelux founded?

    Phagelux was founded in 2014.

  • Who is the founder of Phagelux?

    Mark Engel is the founder of Phagelux.

  • Who is the CEO of Phagelux?

    Mark Engel is the CEO of Phagelux.

  • Where is Phagelux headquartered?

    Phagelux is headquartered in Wuxi, China.

  • What industry is Phagelux in?

    Phagelux’s primary industry is Drug Delivery.

  • Is Phagelux a private or public company?

    Phagelux is a Private company.

  • What is Phagelux’s current revenue?

    The current revenue for Phagelux is 00000.

  • How much funding has Phagelux raised over time?

    Phagelux has raised $10M.

  • Who are Phagelux’s investors?

    Moom Capital, Wuxi Capital, BioTrack Capital, Fosun Pharma, and WuXi Healthcare Investment Consulting have invested in Phagelux.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »